• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Lumito

2.25 SEK+10.32 %22.7. klo 18.29
Less than 1K followers

LUMITO

NGM Growth Market

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+10.32 %
-14.02 %
-15.41 %
-66.22 %
-58.98 %
-96.60 %
-99.21 %
-99.18 %
-98.82 %

Lumito is a Swedish company that develops and markets systems for tissue and biomarker analysis in digital pathology, built on upconverting nanoparticle technology. The company targets healthcare facilities, research and the pharmaceutical sector. The company was formed in 2010 as a spinoff from a research group at Lund University's Department of Atomic Physics and Laser Center. Lumito is headquartered in Lund.

Read more
Market cap
40.43M SEK
Turnover
69.35K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
20.8.
2026

Interim report Q2'26

29.10.
2026

Interim report Q3'26

23.2.
2027

Annual report '26

All
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue K

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Regulatory press release20.07.2026 klo 11.30

Lumito reports positive results from ongoing collaborative research projects – SCIZYS demonstrates high sensitivity across multiple applications

Lumito
Regulatory press release16.07.2026 klo 12.00

Lumito’s founder and Board member Stefan Andersson-Engels presented at the prestigious Gordon Research Conference 2026

Lumito
Regulatory press release14.07.2026 klo 12.00

Lumito and Offspring Biosciences report promising initial results from pilot study evaluating automated immunohistochemistry platform

Lumito

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release09.07.2026 klo 10.00

Lumito and Navinci initiate pilot project – promising initial results from evaluation of combined technology

Lumito
Regulatory press release01.07.2026 klo 09.30

Lumito appoints Pascal Bamford as new Chair of the Scientific Advisory Board

Lumito
Regulatory press release25.06.2026 klo 11.00

Lumito to present two scientific posters and exhibit at the European Congress of Pathology 2026 in Stockholm

Lumito
Regulatory press release11.06.2026 klo 14.00

Lumito strengthens Scientific Advisory Board with internationally leading experts in life science and drug development

Lumito
Regulatory press release27.05.2026 klo 10.00

Lumito awarded Vinnova funding to strengthen regulatory and quality capabilities during commercialisation

Lumito
Regulatory press release25.05.2026 klo 15.15

Subscription price for the exercise of warrants of series TO7 in Lumito AB has been set at 3.5 SEK per share, and the exercise period begins today, 25 May 2026

Lumito
Regulatory press release07.05.2026 klo 09.30

Lumito AB publishes Interim Report Q1 2026

Lumito
Regulatory press release05.05.2026 klo 12.00

Invitation to webinar in connection with Lumito AB’s interim report for Q1 2026

Lumito
Regulatory press release04.05.2026 klo 11.00

Simpler biomarker workflows without compromising sensitivity: new white paper shows how researchers gain reproducible, quantitative IHC results in fewer steps

Lumito
Regulatory press release09.04.2026 klo 09.30

Lumito’s CRO strategy generates revenue through collaboration with Truly Labs AB

Lumito
Regulatory press release02.04.2026 klo 09.30

Lumito and OracleBio initiate a pilot project to explore the combination of high-sensitivity tissue imaging and advanced image analysis

Lumito
Regulatory press release18.03.2026 klo 10.00

Lumito and Tethis complete proof-of-concept study demonstrating compatibility between Lumito’s UCNP imaging and Tethis’ SmartBioSurface® slides

Lumito
Regulatory press release12.03.2026 klo 10.15

Lumito and Offspring Biosciences initiate pilot study to combine automated, standardised workflows with high‑sensitivity tissue analysis

Lumito
Regulatory press release10.03.2026 klo 16.15

Lumito publishes equity research report on Lumito

Lumito
Regulatory press release10.03.2026 klo 12.45

Lumito presents at Analyst Group’s and InFront Direkt Studios’ capital markets day

Lumito
Regulatory press release20.02.2026 klo 09.30

Lumito AB publishes year-end report 2025

Lumito
Regulatory press release18.02.2026 klo 10.20

Lumito and Atlas Antibodies enter strategic partnership to advance high-resolution tissue imaging

Lumito